MK-0952 is a selective and orally active PDE4 inhibitor, with an IC 50 of 0.53 nM. MK-0952 has the potential for Alzheimer’s disease study.
性状
Solid
IC50 & Target[1][2]
PDE4 0.53 nM (IC50)
体内研究(In Vivo)
MK-0952 (10 mg/kg) induces malaise in the rat. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
参考文献
[1]. Michel Gallant, et al. Discovery of MK-0952, a Selective PDE4 Inhibitor for the Treatment of Long-Term Memory Loss and Mild Cognitive Impairment. Epub 2010 Sep 21.[2]. Tingting Pan, et al. Dual Functional Cholinesterase and PDE4D Inhibitors for the Treatment of Alzheimers Disease: Design, Synthesis and Evaluation of tacrine-pyrazolo[3,4-b]pyridine Hybrids. Behav Brain Res. 2016 Apr 15;303:26-33.
溶解度数据
In Vitro: DMSO : 50 mg/mL (103.41 mM; Need ultrasonic)配制储备液